Publications by authors named "Linda Vorrink-de Groot"
Predicting Factors Associated with Hypoglycemia Reduction with Automated Predictive Insulin Suspension in Patients at High Risk of Severe Hypoglycemia: An Analysis from the SMILE Randomized Trial.
Diabetes Technol Ther
September 2020
Article Synopsis
- The SMILE study analyzed how effective the Medtronic MiniMed™ 640G's Suspend before low feature is in reducing severe hypoglycemia in adults with type 1 diabetes at high risk for such events.
- Key factors linked to reduced sensor hypoglycemia included baseline mean number of sensor hypoglycemic events, with a significant impact from the time spent below 54 mg/dL.
- Baseline metrics like HbA1, self-monitoring blood glucose (SMBG) levels, and SMBG variation also played a role, although they were weaker predictors in the absence of continuous glucose monitoring (CGM) data.
Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Lancet Diabetes Endocrinol
June 2019
Background: Hypoglycaemia unawareness and severe hypoglycaemia can increase fear of hypoglycaemia and the risk of subsequent hypoglycaemic events. We aimed to assess the safety and efficacy of insulin pump therapy with integrated continuous glucose monitoring (CGM) and a suspend-before-low feature (Medtronic MiniMed 640G with SmartGuard) in hypoglycaemia-prone adults with type 1 diabetes.
Methods: SMILE was an open-label randomised controlled trial done in people aged 24-75 years with type 1 diabetes for 10 years or longer, HbA values of 5·8-10·0% (40-86 mmol/mol), and at high risk of hypoglycaemia (recent severe hypoglycaemia or hypoglycaemia unawareness defined by a Clarke or Gold score ≥4).